Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Stebbins, G. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Stebbins, G. T.
NEUROLOGY 1993;43:2227
© 1993 American Academy of Neurology

Risk factors for nursing home placement in advanced Parkinson's disease

Christopher G. Goetz, MD and Glenn T. Stebbins, PhD

Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL.

We evaluated the risk factors for nursing home placement of patients with Parkinson's disease (PD) by matching 11 PD patients permanently admitted to nursing homes with two control PD patients remaining at home. Risk factors assessed were motor severity, presence of hallucinations/delusions, and presence of memory problems. The only statistically significant risk factor was the presence of hallucinations/delusions. Motor severity and the presence of memory problems did not have an impact on nursing home placement. There was no risk factor synergy for hallucinations, motor disability, and mental impairment. Since all patients in this series who entered nursing homes remained there permanently, these data suggest that vigorous efforts to control hallucinations may be warranted to prevent nursing home placement.

Address correspondence and reprint requests to Dr. Christopher G. Goetz, Rush-Presbyterian-St. Luke's Medical Center, 1758 West Congress Parkway, Chicago, IL 60612.

Presented at the meeting of the American Neurological Association, Toronto, Ontario, Canada, 1992.

Received February 12, 1993. Accepted for publication in final form April 21, 1993.




This article has been cited by other articles:


Home page
 J Geriatr Psychiatry NeurolHome page
H. H. Fernandez, R. H. See, M. F. Gary, D. Bowers, R. L. Rodriguez, C. Jacobson IV, and M. S. Okun
Depressive Symptoms in Parkinson Disease Correlate With Impaired Global and Specific Cognitive Performance
J Geriatr Psychiatry Neurol, December 1, 2009; 22(4): 223 - 227.
[Abstract] [PDF]

Home page
 BrainHome page
A. M. Meppelink, B. M. de Jong, R. Renken, K. L. Leenders, F. W. Cornelissen, and T. van Laar
Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations
Brain, November 1, 2009; 132(11): 2980 - 2993.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. W. Olanow, M. B. Stern, and K. Sethi
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
N. K. Archibald, M. P. Clarke, U. P. Mosimann, and D. J. Burn
The retina in Parkinson's disease
Brain, May 1, 2009; 132(5): 1128 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. Poewe
Treatments for Parkinson disease--past achievements and current clinical needs
Neurology, February 17, 2009; 72(7_Supplement_2): S65 - S73.
[Abstract] [Full Text] [PDF]

Home page
 Cleveland Clinic Journal of MedicineHome page
M. PANDYA, C. S. KUBU, and M. L. GIROUX
Parkinson disease: Not just a movement disorder
Cleveland Clinic Journal of Medicine, December 1, 2008; 75(12): 856 - 864.
[Abstract] [Full Text] [PDF]

Home page
 Cleveland Clinic Journal of MedicineHome page
B. TOUSI
Movement disorder emergencies in the elderly: Recognizing and treating an often-iatrogenic problem
Cleveland Clinic Journal of Medicine, June 1, 2008; 75(6): 449 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
D. Weintraub and H. I. Hurtig
Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies
Am J Psychiatry, October 1, 2007; 164(10): 1491 - 1498.
[Full Text] [PDF]

Home page
 BrainHome page
P. A. Kempster, D. R. Williams, M. Selikhova, J. Holton, T. Revesz, and A. J. Lees
Patterns of levodopa response in Parkinson's disease: a clinico-pathological study
Brain, August 1, 2007; 130(8): 2123 - 2128.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. Poewe
The need for neuroprotective therapies in Parkinson's disease: A clinical perspective
Neurology, May 23, 2006; 66(10_suppl_4): S2 - S9.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
C. G. Goetz, W. Fan, S. Leurgans, B. Bernard, and G. T. Stebbins
The malignant course of "benign hallucinations" in Parkinson disease.
Arch Neurol, May 1, 2006; 63(5): 713 - 716.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
S. Papapetropoulos
Regional Alpha-Synuclein Aggregation, Dopaminergic Dysregulation, and the Development of Drug-Related Visual Hallucinations in Parkinson's Disease
J Neuropsychiatry Clin Neurosci, May 1, 2006; 18(2): 149 - 157.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
B R Thanvi, T C N Lo, and D P Harsh
Psychosis in Parkinson's disease
Postgrad. Med. J., October 1, 2005; 81(960): 644 - 646.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Diamond and J Jankovic
The effect of deep brain stimulation on quality of life in movement disorders
J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1188 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. G. Goetz, J. Wuu, L. M. Curgian, and S. Leurgans
Hallucinations and sleep disorders in PD: Six-year prospective longitudinal study
Neurology, January 11, 2005; 64(1): 81 - 86.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. T. Stebbins, C. G. Goetz, M. C. Carrillo, K. J. Bangen, D. A. Turner, G. H. Glover, and J. D.E. Gabrieli
Altered cortical visual processing in PD with hallucinations: An fMRI study
Neurology, October 26, 2004; 63(8): 1409 - 1416.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
D. P. Wint, M. S. Okun, and H. H. Fernandez
Psychosis in Parkinson's Disease
J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. G. Goldman, C. G. Goetz, E. Berry-Kravis, S. Leurgans, and L. Zhou
Genetic Polymorphisms in Parkinson Disease Subjects With and Without Hallucinations: An Analysis of the Cholecystokinin System
Arch Neurol, August 1, 2004; 61(8): 1280 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. Marsh, J. R. Williams, M. Rocco, S. Grill, C. Munro, and T. M. Dawson
Psychiatric comorbidities in patients with Parkinson disease and psychosis
Neurology, July 27, 2004; 63(2): 293 - 300.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
M. S. Ismail and I. H. Richard
A Reality Test: How Well Do We Understand Psychosis in Parkinson's Disease?
J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 8 - 18.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
N. Hoeh, L. Gyulai, D. Weintraub, and J. Streim
Pharmacologic Management of Psychosis in the Elderly: A Critical Review
J Geriatr Psychiatry Neurol, December 1, 2003; 16(4): 213 - 218.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
K. A. Jellinger
Parkinson Disease With Old-Age Onset
Arch Neurol, December 1, 2003; 60(12): 1814 - 1815.
[Full Text] [PDF]

Home page
 NeurologyHome page
S. A. Factor, P. J. Feustel, J. H. Friedman, C. L. Comella, C. G. Goetz, R. Kurlan, M. Parsa, R. Pfeiffer, and the Parkinson Study Group
Longitudinal outcome of Parkinson's disease patients with psychosis
Neurology, June 10, 2003; 60(11): 1756 - 1761.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. A. Parashos, D. M. Maraganore, P. C. O'Brien, and W. A. Rocca
Medical Services Utilization and Prognosis in Parkinson Disease: A Population-Based Study
Mayo Clin. Proc., September 1, 2002; 77(9): 918 - 925.
[Abstract] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
J. H. Friedman and H. H. Fernandez
Atypical Antipsychotics in Parkinson-Sensitive Populations
J Geriatr Psychiatry Neurol, January 1, 2002; 15(3): 156 - 170.
[Abstract] [PDF]

Home page
 NeurologyHome page
C. G. Goetz, S. Leurgans, E. J. Pappert, R. Raman, and A. B. Stemer
Prospective longitudinal assessment of hallucinations in Parkinson's disease
Neurology, December 11, 2001; 57(11): 2078 - 2082.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
L. Marsh, C. Lyketsos, and S. G. Reich
Olanzapine for the Treatment of Psychosis in Patients With Parkinson's Disease and Dementia
Psychosomatics, December 1, 2001; 42(6): 477 - 481.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. W. Olanow, R. L. Watts, and W. C. Koller
An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
Neurology, June 12, 2001; 56(suppl_5): S1 - S88.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S Holroyd, L Currie, and G F Wooten
Prospective study of hallucinations and delusions in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, June 1, 2001; 70(6): 734 - 738.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
I. H. Richard and J. Nutt
Worsening of motor function in Parkinson's disease: A ""typical"" response to ""atypical"" antipsychotic medications
Neurology, September 26, 2000; 55(6): 748 - 749.
[Full Text] [PDF]

Home page
 NeurologyHome page
C. G. Goetz, L. M. Blasucci, S. Leurgans, and E. J. Pappert
Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
Neurology, September 26, 2000; 55(6): 789 - 794.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A. Schrag, M. Jahanshahi, and N. Quinn
What contributes to quality of life in patients with Parkinson's disease?
J. Neurol. Neurosurg. Psychiatry, September 1, 2000; 69(3): 308 - 312.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
I. Arnulf, A.-M. Bonnet, P. Damier, B.-P. Bejjani, D. Seilhean, J.-P. Derenne, and Y. Agid
Hallucinations, REM sleep, and Parkinson's disease: A medical hypothesis
Neurology, July 25, 2000; 55(2): 281 - 288.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. J. Weiner, A. Minagar, and L. M. Shulman
Quetiapine for L-dopa-induced psychosis in PD
Neurology, April 11, 2000; 54(7): 1538 - 1538.
[Full Text] [PDF]

Home page
 BrainHome page
G. Fenelon, F. Mahieux, R. Huon, and M. Ziegler
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Brain, April 1, 2000; 123(4): 733 - 745.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
L. Marsh
Neuropsychiatric Aspects of Parkinson's Disease
Psychosomatics, February 1, 2000; 41(1): 15 - 23.
[Abstract] [Full Text]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
D. Aarsland, J. P. Larsen, N. G. Lim, and E. Tandberg
Olanzapine for Psychosis in Patients With Parkinson's Disease With and Without Dementia
J Neuropsychiatry Clin Neurosci, August 1, 1999; 11(3): 392 - 394.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
D. Aarsland, J. P. Larsen, J. L. Cummings, and K. Laake
Prevalence and Clinical Correlates of Psychotic Symptoms in Parkinson Disease: A Community-Based Study
Arch Neurol, May 1, 1999; 56(5): 595 - 601.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
The Parkinson Study Group
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
N. Engl. J. Med., March 11, 1999; 340(10): 757 - 763.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
I. Litvan, J. L Cummings, and M. Mega
Neuropsychiatric features of corticobasal degeneration
J. Neurol. Neurosurg. Psychiatry, November 1, 1998; 65(5): 717 - 721.
[Abstract] [Full Text]

Home page
 NEJMHome page
A. E. Lang and A. M. Lozano
Parkinson's Disease- Second of Two Parts
N. Engl. J. Med., October 15, 1998; 339(16): 1130 - 1143.
[Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
D. M. Roane, J. D. Rogers, J. H. Robinson, and T. E. Feinberg
Delusional Misidentification in Association With Parkinsonism
J Neuropsychiatry Clin Neurosci, May 1, 1998; 10(2): 194 - 198.
[Abstract] [Full Text]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
M. A. Parsa and B. Bastani
Quetiapine (Seroquel) in the Treatment of Psychosis in Patients With Parkinson's Disease
J Neuropsychiatry Clin Neurosci, May 1, 1998; 10(2): 216 - 219.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by AAN Enterprises, Inc.